Sacituzumab (Anti-TROP-2) is a recombinant humanized monoclonal antibody targeting trophoblast cell-antigen2 (TROP-2). Sacituzumab has been used for the research of metastatic triple-negative breast cancer.
Sacituzumab-SAP is a bonded toxin between a biotinylated recombinant humanized antibody to TROP-2 and the secondary conjugate Streptavidin-ZAP containing the ribosome-inactivating protein, saporin.
Sacituzumab-SAP eliminates cells expressing human TROP-2. All other cells are left untouched.
The following control is included for validating the specificity of the beta conjugate: BIgG-SAP Human (Cat. #IT-77)
This product is being offered as part of our Beta Testing program. It has saporin activity confirmed, peptide sequences published/confirmed, and/or antibody binding specificity published/confirmed. It has not been characterized or reported in scientific literature. The researcher who first publishes data* will receive a $500 credit for use on ATS products.
*Data subject to review by the scientific team at ATS. See complete details here.
keywords: sacituzumab, Trop-2, Anti-Trop-2, tropoblast cell-antigen2, metastatic, breast cancer, triple-negative, immunotoxin, streptavidin, saporin